New data presented at ASTRO 2026 show Artera’s multimodal AI prostate cancer biomarker delivers consistent prognostic results across diverse patient populations, supporting its use in personalized treatment decisions, according to five abstracts.
CMS has released preliminary 2027 CLFS rates, with data showing weighted median payment cuts for over 1,100 test codes; annual reductions are capped at 15% from 2027 to 2029 under current policy.
Renew Biotechnologies and Mayo Clinic have partnered to evaluate NeuroLens, a cfDNA-based test, for monitoring central nervous system injury and disease progression in multiple sclerosis and related neuroimmunologic conditions.
Laboratories hold years of patient test results, but much of that data remains fragmented and underused despite its potential value for patient care and reimbursement.
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.
